Epix Pharmaceuticals, Inc. Announces August 25, 2009 For The Auction Sale Of Equipment And September

< BACK TO COMPANY starstarstarstarstar   Business - Company Press Release
5th August 2009, 06:01am - Views: 706





Business Company Joseph F. Finn, Jr., C.P.A. 1 image



MEDIA RELEASE PR35603


EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and

September 30, 2009 for the Auction Sale of the Intellectual Property


WELLESLEY HILLS, Mass., Aug. 5 /PRNewswire-AsiaNet/ --


    Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that August 25, 2009 is the date for the sale of

the equipment and September 30, 2009 is the date for the sale of the intellectual property.


    EPIX's products and services focus on the discovery and development of novel therapeutics through

the use of its proprietary and highly efficient in silico drug discovery platform.  The company has a

pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of

the central nervous system and lung conditions.  In addition, EPIX has programs related to its MRI

imaging business.  EPIX also has collaborations with several leading pharmaceutical and research

foundations.


    The intellectual property, regulatory dossier, fixed assets and clinical inventory will be sold at auction

on September 30, 2009.


    Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained

from Finn's Office - jffinnjr@earthlink.net or 781-237-8840.  They will then receive a bid package.


    About Joseph F. Finn, Jr., C.P.A.

    Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified

Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management

consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for

the benefit of creditors and liquidating agent for a corporation.  He has been involved in a number of

loan workouts and bankruptcy cases for thirty-five (35) years.  His most recent Assignments for the

Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect

Therapeutics, Inc.


    For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or

jffinnjr@earthlink.net


SOURCE: Joseph F. Finn, Jr., C.P.A.


    CONTACT: Joseph F. Finn, Jr., C.P.A., 

                       +1-781-237-8840, 

                       jffinnjr@earthlink.net








news articles logo NEWS ARTICLES
Contact News Articles |Remove this article